Vivos Therapeutics, Inc. (VVOS) stock
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.08−0.00 (-3.04%)
Close on Nov 17, 2026Market cap $1.60MP/E –Yield –
Vivos Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vivos Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$17.13M. For fiscal 2025 it was -$15.26M. The highest annual figure on record is -$5.34M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.26M | – |
| FY2024 | Dec 31, 2024 | -$12.69M | – |
| FY2023 | Dec 31, 2023 | -$11.95M | – |
| FY2022 | Dec 31, 2022 | -$19.59M | – |
| FY2021 | Dec 31, 2021 | -$15.74M | – |
| FY2020 | Dec 31, 2020 | -$5.68M | – |
| FY2019 | Dec 31, 2019 | -$5.34M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.81M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.16M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.49M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.52M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.86M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.54M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.66M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.08M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.12M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$674.44K | – |
| Q2 FY2020 | Jun 30, 2020 | -$950.60K | – |
| Q1 FY2020 | Mar 31, 2020 | -$436.91K | – |
See a number that looks wrong?